Off-the-shelf therapy development
The company is developing tab-cel for EBV-positive post-transplant lymphoproliferative disease and other EBV-driven diseases.
Source: LinkedIn company description · Retrieved October 13, 2026
Atara Biotherapeutics is an allogeneic T-cell immunotherapy company developing off-the-shelf therapies for patients with serious diseases.
Its platform uses EBV T cells and can incorporate engineered CARs or TCRs for EBV-associated or other serious diseases. The platform does not require TCR or HLA gene editing.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
The company is developing tab-cel for EBV-positive post-transplant lymphoproliferative disease and other EBV-driven diseases.
Source: LinkedIn company description · Retrieved October 13, 2026
The company’s CAR-T immunotherapies are for solid tumors and hematologic malignancies.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 4, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 2, 2026, September 14, 2026, September 15, 2026, September 17, 2026, September 18, 2026, September 19, 2026, September 21, 2026, September 26, 2026, September 27, 2026, September 30, 2026, October 8, 2026 and October 10, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.